Structured Review

Tocris pf 57328
(A) Representative images of Vinculin-mIFP-transfected HT1080 cells carrying the OptoKANK constructs before and after blue light illumination of the focal adhesion (yellow dotted line) for control cells (Ctrl), cells treated with FRAX1036, <t>PF-57328,</t> Kinesore, as well as in APC-depleted, αTAT1-depleted cells, and in FAK -/- knockout MEF cells. Graph shows the normalized mean vinculin intensity after the illumination of cells treated as indicated (Data are presented as mean ± s.e.m; Ctrl, n =18; Nocodazole, n = 12; FRAX1036, n = 15; PF-573228, n = 10; FAK KO -/- , n = 8; Kinesore, n = 11; siRNA APC, n = 18; αTAT1, n = 10). Immunoblots of GEF-H1, p-PAK1/2, APC and GAPDH are shown in the black box. (B) Representative images of Vinculin-mIFP-transfected HT1080 cells carrying the OptoKANK constructs before and after blue light illumination on the focal adhesion (yellow dotted line) for cells treated with FRAX1036, and cells treated with FRAX1036 simultaneously with the contractility activator CNO3. Graph shows the normalized mean vinculin intensity after the illumination for cells under these conditions (Data are presented as mean ± s.e.m; Ctrl, n = 18; Noco, n = 12; PAK inhibitor, n = 15, PAK inhibitor + CN03, n = 10). (C) Representative images of Vinculin-mIFP-transfected HT1080 cells carrying the OptoKANK constructs before and after blue light illumination of the focal adhesion (yellow dotted line) for cells treated with FAK inhibitor PF-57328, Kinesine-1 modulating drug Kinesore, and APC-depleted cells and in such cells treated with Rho activator CNO3. Graph shows the normalized mean vinculin intensity after the illumination for cells under treatments mentioned above (Data are presented as mean ± s.e.m; Ctrl, n =18; Nocodazole, CNO3, n = 8; Kinesore, n = 10; Kinesore + CN03, =n = 16; APC KD, n = 18; APC KD + CNO3, n = 14, FAK inhibitor; n = 10; FAK inhibitor + CNO3, n = 10).
Pf 57328, supplied by Tocris, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pf 57328/product/Tocris
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
pf 57328 - by Bioz Stars, 2024-02
86/100 stars

Images

1) Product Images from "Focal adhesions are controlled by microtubules through local contractility regulation"

Article Title: Focal adhesions are controlled by microtubules through local contractility regulation

Journal: bioRxiv

doi: 10.1101/2023.04.17.535593

(A) Representative images of Vinculin-mIFP-transfected HT1080 cells carrying the OptoKANK constructs before and after blue light illumination of the focal adhesion (yellow dotted line) for control cells (Ctrl), cells treated with FRAX1036, PF-57328, Kinesore, as well as in APC-depleted, αTAT1-depleted cells, and in FAK -/- knockout MEF cells. Graph shows the normalized mean vinculin intensity after the illumination of cells treated as indicated (Data are presented as mean ± s.e.m; Ctrl, n =18; Nocodazole, n = 12; FRAX1036, n = 15; PF-573228, n = 10; FAK KO -/- , n = 8; Kinesore, n = 11; siRNA APC, n = 18; αTAT1, n = 10). Immunoblots of GEF-H1, p-PAK1/2, APC and GAPDH are shown in the black box. (B) Representative images of Vinculin-mIFP-transfected HT1080 cells carrying the OptoKANK constructs before and after blue light illumination on the focal adhesion (yellow dotted line) for cells treated with FRAX1036, and cells treated with FRAX1036 simultaneously with the contractility activator CNO3. Graph shows the normalized mean vinculin intensity after the illumination for cells under these conditions (Data are presented as mean ± s.e.m; Ctrl, n = 18; Noco, n = 12; PAK inhibitor, n = 15, PAK inhibitor + CN03, n = 10). (C) Representative images of Vinculin-mIFP-transfected HT1080 cells carrying the OptoKANK constructs before and after blue light illumination of the focal adhesion (yellow dotted line) for cells treated with FAK inhibitor PF-57328, Kinesine-1 modulating drug Kinesore, and APC-depleted cells and in such cells treated with Rho activator CNO3. Graph shows the normalized mean vinculin intensity after the illumination for cells under treatments mentioned above (Data are presented as mean ± s.e.m; Ctrl, n =18; Nocodazole, CNO3, n = 8; Kinesore, n = 10; Kinesore + CN03, =n = 16; APC KD, n = 18; APC KD + CNO3, n = 14, FAK inhibitor; n = 10; FAK inhibitor + CNO3, n = 10).
Figure Legend Snippet: (A) Representative images of Vinculin-mIFP-transfected HT1080 cells carrying the OptoKANK constructs before and after blue light illumination of the focal adhesion (yellow dotted line) for control cells (Ctrl), cells treated with FRAX1036, PF-57328, Kinesore, as well as in APC-depleted, αTAT1-depleted cells, and in FAK -/- knockout MEF cells. Graph shows the normalized mean vinculin intensity after the illumination of cells treated as indicated (Data are presented as mean ± s.e.m; Ctrl, n =18; Nocodazole, n = 12; FRAX1036, n = 15; PF-573228, n = 10; FAK KO -/- , n = 8; Kinesore, n = 11; siRNA APC, n = 18; αTAT1, n = 10). Immunoblots of GEF-H1, p-PAK1/2, APC and GAPDH are shown in the black box. (B) Representative images of Vinculin-mIFP-transfected HT1080 cells carrying the OptoKANK constructs before and after blue light illumination on the focal adhesion (yellow dotted line) for cells treated with FRAX1036, and cells treated with FRAX1036 simultaneously with the contractility activator CNO3. Graph shows the normalized mean vinculin intensity after the illumination for cells under these conditions (Data are presented as mean ± s.e.m; Ctrl, n = 18; Noco, n = 12; PAK inhibitor, n = 15, PAK inhibitor + CN03, n = 10). (C) Representative images of Vinculin-mIFP-transfected HT1080 cells carrying the OptoKANK constructs before and after blue light illumination of the focal adhesion (yellow dotted line) for cells treated with FAK inhibitor PF-57328, Kinesine-1 modulating drug Kinesore, and APC-depleted cells and in such cells treated with Rho activator CNO3. Graph shows the normalized mean vinculin intensity after the illumination for cells under treatments mentioned above (Data are presented as mean ± s.e.m; Ctrl, n =18; Nocodazole, CNO3, n = 8; Kinesore, n = 10; Kinesore + CN03, =n = 16; APC KD, n = 18; APC KD + CNO3, n = 14, FAK inhibitor; n = 10; FAK inhibitor + CNO3, n = 10).

Techniques Used: Transfection, Construct, Knock-Out, Western Blot

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Tocris pf 57328
    (A) Representative images of Vinculin-mIFP-transfected HT1080 cells carrying the OptoKANK constructs before and after blue light illumination of the focal adhesion (yellow dotted line) for control cells (Ctrl), cells treated with FRAX1036, <t>PF-57328,</t> Kinesore, as well as in APC-depleted, αTAT1-depleted cells, and in FAK -/- knockout MEF cells. Graph shows the normalized mean vinculin intensity after the illumination of cells treated as indicated (Data are presented as mean ± s.e.m; Ctrl, n =18; Nocodazole, n = 12; FRAX1036, n = 15; PF-573228, n = 10; FAK KO -/- , n = 8; Kinesore, n = 11; siRNA APC, n = 18; αTAT1, n = 10). Immunoblots of GEF-H1, p-PAK1/2, APC and GAPDH are shown in the black box. (B) Representative images of Vinculin-mIFP-transfected HT1080 cells carrying the OptoKANK constructs before and after blue light illumination on the focal adhesion (yellow dotted line) for cells treated with FRAX1036, and cells treated with FRAX1036 simultaneously with the contractility activator CNO3. Graph shows the normalized mean vinculin intensity after the illumination for cells under these conditions (Data are presented as mean ± s.e.m; Ctrl, n = 18; Noco, n = 12; PAK inhibitor, n = 15, PAK inhibitor + CN03, n = 10). (C) Representative images of Vinculin-mIFP-transfected HT1080 cells carrying the OptoKANK constructs before and after blue light illumination of the focal adhesion (yellow dotted line) for cells treated with FAK inhibitor PF-57328, Kinesine-1 modulating drug Kinesore, and APC-depleted cells and in such cells treated with Rho activator CNO3. Graph shows the normalized mean vinculin intensity after the illumination for cells under treatments mentioned above (Data are presented as mean ± s.e.m; Ctrl, n =18; Nocodazole, CNO3, n = 8; Kinesore, n = 10; Kinesore + CN03, =n = 16; APC KD, n = 18; APC KD + CNO3, n = 14, FAK inhibitor; n = 10; FAK inhibitor + CNO3, n = 10).
    Pf 57328, supplied by Tocris, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pf 57328/product/Tocris
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pf 57328 - by Bioz Stars, 2024-02
    86/100 stars
      Buy from Supplier

    Image Search Results


    (A) Representative images of Vinculin-mIFP-transfected HT1080 cells carrying the OptoKANK constructs before and after blue light illumination of the focal adhesion (yellow dotted line) for control cells (Ctrl), cells treated with FRAX1036, PF-57328, Kinesore, as well as in APC-depleted, αTAT1-depleted cells, and in FAK -/- knockout MEF cells. Graph shows the normalized mean vinculin intensity after the illumination of cells treated as indicated (Data are presented as mean ± s.e.m; Ctrl, n =18; Nocodazole, n = 12; FRAX1036, n = 15; PF-573228, n = 10; FAK KO -/- , n = 8; Kinesore, n = 11; siRNA APC, n = 18; αTAT1, n = 10). Immunoblots of GEF-H1, p-PAK1/2, APC and GAPDH are shown in the black box. (B) Representative images of Vinculin-mIFP-transfected HT1080 cells carrying the OptoKANK constructs before and after blue light illumination on the focal adhesion (yellow dotted line) for cells treated with FRAX1036, and cells treated with FRAX1036 simultaneously with the contractility activator CNO3. Graph shows the normalized mean vinculin intensity after the illumination for cells under these conditions (Data are presented as mean ± s.e.m; Ctrl, n = 18; Noco, n = 12; PAK inhibitor, n = 15, PAK inhibitor + CN03, n = 10). (C) Representative images of Vinculin-mIFP-transfected HT1080 cells carrying the OptoKANK constructs before and after blue light illumination of the focal adhesion (yellow dotted line) for cells treated with FAK inhibitor PF-57328, Kinesine-1 modulating drug Kinesore, and APC-depleted cells and in such cells treated with Rho activator CNO3. Graph shows the normalized mean vinculin intensity after the illumination for cells under treatments mentioned above (Data are presented as mean ± s.e.m; Ctrl, n =18; Nocodazole, CNO3, n = 8; Kinesore, n = 10; Kinesore + CN03, =n = 16; APC KD, n = 18; APC KD + CNO3, n = 14, FAK inhibitor; n = 10; FAK inhibitor + CNO3, n = 10).

    Journal: bioRxiv

    Article Title: Focal adhesions are controlled by microtubules through local contractility regulation

    doi: 10.1101/2023.04.17.535593

    Figure Lengend Snippet: (A) Representative images of Vinculin-mIFP-transfected HT1080 cells carrying the OptoKANK constructs before and after blue light illumination of the focal adhesion (yellow dotted line) for control cells (Ctrl), cells treated with FRAX1036, PF-57328, Kinesore, as well as in APC-depleted, αTAT1-depleted cells, and in FAK -/- knockout MEF cells. Graph shows the normalized mean vinculin intensity after the illumination of cells treated as indicated (Data are presented as mean ± s.e.m; Ctrl, n =18; Nocodazole, n = 12; FRAX1036, n = 15; PF-573228, n = 10; FAK KO -/- , n = 8; Kinesore, n = 11; siRNA APC, n = 18; αTAT1, n = 10). Immunoblots of GEF-H1, p-PAK1/2, APC and GAPDH are shown in the black box. (B) Representative images of Vinculin-mIFP-transfected HT1080 cells carrying the OptoKANK constructs before and after blue light illumination on the focal adhesion (yellow dotted line) for cells treated with FRAX1036, and cells treated with FRAX1036 simultaneously with the contractility activator CNO3. Graph shows the normalized mean vinculin intensity after the illumination for cells under these conditions (Data are presented as mean ± s.e.m; Ctrl, n = 18; Noco, n = 12; PAK inhibitor, n = 15, PAK inhibitor + CN03, n = 10). (C) Representative images of Vinculin-mIFP-transfected HT1080 cells carrying the OptoKANK constructs before and after blue light illumination of the focal adhesion (yellow dotted line) for cells treated with FAK inhibitor PF-57328, Kinesine-1 modulating drug Kinesore, and APC-depleted cells and in such cells treated with Rho activator CNO3. Graph shows the normalized mean vinculin intensity after the illumination for cells under treatments mentioned above (Data are presented as mean ± s.e.m; Ctrl, n =18; Nocodazole, CNO3, n = 8; Kinesore, n = 10; Kinesore + CN03, =n = 16; APC KD, n = 18; APC KD + CNO3, n = 14, FAK inhibitor; n = 10; FAK inhibitor + CNO3, n = 10).

    Article Snippet: Pharmacological treatments were performed using the following concentrations of inhibitors or activators: 1 μM for Nocodazole (Sigma-Aldrich), 0.4 μM for Y-27632 dihydrochloride (Sigma-Aldrich), 20 mM for Acetyl-Calpastatin (Tocris, Cat. No. 2950), Monastrol (Merk, cat. No. 254753-54-3), 80 µM for Dynasore (Abcam Cat. No. 120192), Batimastat (Tocris Cat. No. 2961), Tubacin (Cat. No. 3402), MAP4K4-IN-3 (MedChemExpress, Cat. No.: HY-125012), 1 µM for FRAX1036 (MedChemExpress Cat. No. HY-19538), 50 µM for Kinesore (Cat. No. 6664), 5 µM for PF-57328 (Tocris, Cat. No. 3239), and 1 μg ml - for Rho activator II (CNO3, Cytoskeleton).

    Techniques: Transfection, Construct, Knock-Out, Western Blot